Nebivololo Eg

Nebivolol, the active ingredient in Nebivololo Eg, is a beta blocker presented as an oral tablet for oral use. It is indicated for the management of hypertension and for reducing morbidity in patients with chronic heart failure, primarily in adult populations.

GNH USA supplies Nebivololo Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory‑aligned distribution for this cardiovascular therapy. The company adheres to stringent quality standards and offers global logistics support to meet the needs of healthcare providers across diverse markets.

Nebivolol is a selective β1‑adrenergic blocker used in cardiovascular disease management. - Hypertension: lowers blood pressure by reducing cardiac output and peripheral vascular resistance. - Chronic heart failure: improves left ventricular function and decreases risk of hospitalization. - Post‑myocardial infarction: reduces mortality and recurrent cardiac events in eligible patients.

Nebivolol may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Dizziness: sensation of light‑headedness, especially when standing quickly. - Fatigue: generalized tiredness that may lessen with continued use. - Bradycardia: slower than normal heart rate, usually asymptomatic. - Nausea: mild gastrointestinal upset. - Peripheral edema: swelling of ankles or lower legs.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Hypotension: significant drop in blood pressure causing faintness. - Bronchospasm: airway constriction, particularly in patients with reactive airway disease. - Atrioventricular block: impaired electrical conduction of the heart. - Allergic reactions: rash, itching, or swelling that may indicate hypersensitivity. - Hepatic dysfunction: abnormal liver enzymes indicating possible liver injury.

When prescribing Nebivolol, clinicians should consider several safety measures. - Dose adjustment in renal impairment: reduce dose in patients with severe renal dysfunction. - Monitor blood pressure: avoid excessive hypotension, especially after dose changes. - Assess heart rate: contraindicated in patients with baseline bradycardia. - Avoid abrupt discontinuation: sudden stop may precipitate rebound hypertension. - Pregnancy and lactation: safety not established; use only if potential benefit justifies the risk. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture.

Nebivolol can interact with various medications, requiring careful management.

Major Interactions (Avoid): - Concomitant use with other beta‑blockers: additive bradycardia and hypotension. - Non‑selective beta‑blockers: increased risk of severe bradycardia. - Calcium channel blockers (verapamil, diltiazem): may cause atrioventricular block. - Clonidine abrupt withdrawal: can precipitate rebound hypertension.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance hypotensive effect; monitor volume status. - ACE inhibitors or ARBs: watch renal function and potassium levels. - Antidiabetic agents: beta‑blockade may mask hypoglycemia symptoms.